News

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...
Targeted Oncology3h
Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer
In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...
Applied Clinical Trials Online6h
KEYNOTE-B96 Trial Shows Keytruda is First Immunotherapy to Improve Overall Survival in Platinum-Resistant Ovarian Cancer
Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...
Fierce Pharma6h
Merck's Keytruda finds a path in ovarian cancer with phase 3 win in certain recurrent patients
Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...
Targeted Oncology6h
Pembrolizumab Improves PFS in Recurrent Ovarian Cancer
The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...
Merck says late-stage trial for Keytruda regimen hit main goal in ovarian cancer
Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...
Cancer Therapy Advisor17h
Avmapki Plus Fakzynja Granted Accelerated Approval for Ovarian Cancer
The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.